linjc16/ctgov huggingface dataset:
TOETVA Feasibility and Complications - Single Center First Experience

Study Overview
=================
Brief Summary
-----------------
All participants who underwent (or will undergo) a transoral endoscopic thyroidectomy via vestibular approach (TOETVA) at the investigators' center are observed for complications and feasibility of this surgery. Anonymised data relevant to the participants' condition will be used.

Official Title
-----------------
Feasibility and Complications After Transoral Endoscopic Thyroidectomy Via Vestibular Approach (TOETVA) - a Single-Center First Experience Case Series and Systematic Review

Conditions
-----------------
Thyroid Gland Disease, Surgery

Intervention / Treatment
-----------------
* Procedure: TOETVA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent (or will undergo) a transoral endoscopic thyroidectomy via vestibular approach (TOETVA) at the investigators' center Exclusion Criteria: Patients who did not undergo (or will not undergo) a TOETVA at the investigators' center
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TOETVA<br>All patients who underwent a transoral endoscopic thyroidectomy via vestibular approach (TOETVA) at the investigators' center. | Procedure: TOETVA<br>* Completed procedure.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications initial | Complications after performed surgery | Immediately postoperative (during hospitalization) | 
| Complications before follow-up | Complications after performed surgery | If premature presentation occurs (admission after discharge and before follow-up consultation at 1 month after surgery) | 
| Complications before follow-up | Complications after performed surgery | Data at first follow-up visit will be reported. First follow-up visit will be at (average) 1 month after discharge. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TOETVA, NOTES, Surgery, Endocrine, Thyroid, Case Series
Role of Oxidized Regenerated Cellulose (ORC) Applied to Dirty Surgical Wounds

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether oxidized regenerated cellulose (ORC) is effective to reduce the risk of surgical site infections (SSI).

Detailed Description
-----------------
Surgical site infections (SSI) have significant clinical and economic repercussions since they still are the most common cause of nosocomial infections in surgical patients. It is important to bear in mind the growing number of SSI due to antibiotic-resistant microorganisms.

Official Title
-----------------
The Role of Oxidized Regenerated Cellulose in Preventing Infections at the Surgical Site: Prospective, Randomized Study in 98 Patients Affected by a Dirty Wound

Conditions
-----------------
Infections

Intervention / Treatment
-----------------
* Device: oxidized regenerated cellulose (Fibrillar SURGICEL)
* Device: iodoform gauze


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have an ileostomy or a colostomy are candidates for an elective surgical procedure of ostomy closure Exclusion Criteria: immunodeficiency chronic use of corticosteroids or antibiotics chemotherapy and/or radiotherapy in the last 30 days before closure of the stoma concomitant foci of infection
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: group A-the treatment group<br>Group A-patients have their wound, the site of the previous stoma, wad with ORC | Device: oxidized regenerated cellulose (Fibrillar SURGICEL)<br>* one gauze made of ORC<br>* Other names: Fibrillar SURGICEL (Ethicon, Somerville, New Jersey);|
| Active Comparator: group B-the control group<br>control group-patients have their wound wad with iodoform gauze | Device: iodoform gauze<br>* one iodoform gauze<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to reduce the microbial load and, consequently, the infection rate as compared to conventional local wound treatment |  | third post-operative day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ORC (oxidized regenerated cellulose), SSI (Surgical site infections)
The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing

Study Overview
=================
Brief Summary
-----------------
In the 21st century, threats to human health of new respiratory infectious diseases increased. The project aim is to establish pneumonia pathogens network in Beijing and understand the pathogen spectrum distribution.

Official Title
-----------------
The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing

Conditions
-----------------
Community Acquired Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed community acquired pneumonia Age≥14 ys New appear of cough or cough become severe New infiltration showed by chest radiology(x-ray or CT) Fever T>37.8o C or <35.6o C White blood cell>10,000/mm3 , left shift or leukopenia<4000/ul） Exclusion Criteria: Pregnancy or breast-feeding Over one week after the onset of symptoms HIV infection Recent 90-day hospitalized history(length of stay greater than 2 days) Live in nursing homes or rehabilitation hospitals

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Community acquired pneumonia,age≥14 ys<br>Patients with community acquired pneumonia,age≥14 ys and less than one week after the onset of symptoms, without pregnancy,breast-feeding,HIV infection,recent 90-day hospitalized history and in nursing homes or rehabilitation hospitals | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to resolution of all symptoms (defined as the period from start of study-drug to relief of fever) |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| If duration of symptoms long, follow-up 30 days. |  | one year | 
| In case of early termination:death;diagnosed tuberculosis;diagnosed lung cancer and HIV infection |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pathogen
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.

Study Overview
=================
Brief Summary
-----------------
Compare the efficacy and safety of an investigational nasal spray compared with placebo nasal spray in the treatment of seasonal allergic rhinitis. Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the pollen from trees, grasses, and weeds. Commonly referred to as 'hay fever', it is characterized by sneezing, nasal congestion and pruritus, rhinorrhea, and pruritic, watery, red eyes.

Official Title
-----------------
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis in Europe

Conditions
-----------------
Rhinitis, Allergic, Seasonal

Intervention / Treatment
-----------------
* Drug: GW685698X


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Informed consent. Must be an outpatient. Females must be using appropriate contraception. Must have diagnosis of seasonal allergic rhinitis, adequate exposure to allergen. Must be able to comply with study procedures. Must be literate. Exclusion criteria: A significant concomitant medical condition. Use of corticosteroids or allergy or medications or tobacco. Clinically significant abnormal ECG. Laboratory abnormality. Positive pregnancy test. Allergy to any component of the investigational product.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GW685698X|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline over the entire treatment period in daily, reflective, total nasal symptom scores (rTNSS). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline over the entire tx period in AM, pre-dose iTNS. Mean change from baseline over the entire treatment period in rTOSS. Overall evaluation of response to therapy. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Seasonal Allergic Rhinitis Intranasal Corticosteroid
Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma

Study Overview
=================
Brief Summary
-----------------
The aim of the study was to compare the effect of fenoterol metered dose inhaler with disodium cromoglycate (DSCG) metered dose inhaler on the lymphocyte β2-receptor population as well as on the clinical findings in patients with bronchial asthma over a two-week period of treatment.

Official Title
-----------------
Effect of Fenoterol Metered Dose Inhaler (0.1 mg) on the Beta-receptor Population on Lymphocytes and the Clinical Findings Compared With Treatment With DSCG Metered Dose Inhaler in Patients With Bronchial Asthma.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Fenoterol MDI
* Drug: DSCG MDI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sex: male and female age: 18 years or over bronchial asthma, diagnosis confirmed by history and positive inhalation challenge test (unspecific challenge with carbachol, PD100SRaw)) severity of asthma mild to moderate or asthmatic in symptom-free intervals Raw ≤ 5 cm H2O/l/s no antiasthmatic treatment in the week (steroid therapy: two weeks) before the start of the study Exclusion Criteria: clinically significant, concomitant haematological, cardiac, renal, hepatic or metabolic diseases intercurrent diseases, e.g. severe respiratory infections patients who cannot do without the following preparations during the 5-week trial: inhaled/oral steroids theophylline antihistamine, antiallergic drugs inhaled/oral sympathomimetics anticholinergics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fenoterol metered dose inhaler (MDI)<br> | Drug: Fenoterol MDI<br> <br> |
| Active Comparator: DSCG MDI<br> | Drug: DSCG MDI<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Airway resistance (Raw) |  | after 2 weeks | 
| Number of binding sites of the β2 receptors per lymphocytes (BS/LY) |  | after 2 weeks |
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)

Study Overview
=================
Brief Summary
-----------------
This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC. Patients will be followed up approximately 6 months after initial visit. Selection of Study Population: Women can be enrolled after decision for treatment with Yasmin or any other OC has been made. Physicians should consult the full prescribing information for the respective OC before enrolling patients and familiarize themselves with the safety information in the product package label.

Official Title
-----------------
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC))

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Drug: EE30/DRSP (Yasmin, BAY86-5131)
* Drug: Any other OC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who have been found eligible for OC use and have newly been prescribed an OC in accordance with the terms of the respective marketing authorization Starter (first-ever user of an OC) and switcher from another OC (incl. women with a history of OC use) Exclusion Criteria: The contraindications and warnings of the Summary of Product Characteristics must be followed.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: EE30/DRSP (Yasmin, BAY86-5131)<br>* Patients under regular daily life treatment receiving Yasmin according to local drug information<br>|
| Group 2<br> | Drug: Any other OC<br>* Patients under regular daily life treatment receiving any other OC according to local drug information<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyses of continuation rates and compliance stratified by the subject's knowledge on the respective topics and time spent for counseling. |  | After 3 months and at end of study after approx. 6 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analyses stratified by baseline factors such as age group, presence or absence of cycle disorders, and history of oral contraceptive method will be performed as well. |  | After 3 months and after approx. 6 months. | 
| Special attention will be paid to serious adverse events and unexpected or unlisted ADRs. |  | Over 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Compliance, Hormonal Contraception
Acute Presentation and Management of Abdominal Tuberculosis: A Ten-year Experience at a Tertiary Care Center in Pakistan

Study Overview
=================
Brief Summary
-----------------
A prospective interventional study was conducted in Services Instituton of Medical Sciences all patients who underwent emergency laparotomy from 2008-2018 due to abdominal tuberculosis. Data were analyzed using SPSS version 21

Official Title
-----------------
Acute Presentation and Management of Abdominal Tuberculosis: A Ten-year Experience at a Tertiary Care Center in Pakistan

Conditions
-----------------
Tuberculosis; Abdomen

Intervention / Treatment
-----------------
* Procedure: exploratory laparotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both sexes and age between years and 90 years Patients presenting with acute abdomen and who underwent exploratory laparotomy Patients who diagnosis confirmed on biopsy (caseating granulomas) Exclusion Criteria: Peritoneal tuberculosis Other causes of acute abdomen (Typhoid perforation) Patients diagnosed with abdominal tuberculosis and on conservative management

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Exploratory Laparotomy<br>Exploratory Laparotomy of patients presenting acute abdomen and whose diagnosis later on confirmed on histopathology to be tuberculosis | Procedure: exploratory laparotomy<br>* Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who develop complications after surgery | Complications of surgery like leakage of gut content, enterocutaneous fistula, intestinal obstruction | 9 months | 
| Percentage of patients who develop recurrence of abdominal tuberculosis (elevated ESR, CT scan findings of abdominal tuberculosis) | Recurrence of abdominal tuberclosis assessed by ESR, CT scan Abdomen, Biopsy | 1 year | 
| Mortality rate | death due to postoperative complications | 9 months |
Management of Congenial Clasped Thumb

Study Overview
=================
Brief Summary
-----------------
Congenital clasped thumb is a rare progressive flexion and adduction deformity presenting with heterogenous congenital abnormalities.(1, 2) It is confused with trigger finger deformity due to fixated flexion deformity of the thumb. In congenital trigger finger entrapment is present at A1 pulley level due to fusiform enlargement of flexor pollicis longus tendon

Detailed Description
-----------------
The main problem is the deficient extensor tendon mechanism of thumb due to functional and structural causes. \ Although in congenital clasp finger deformity there are thumb flexion deformity due to extensor tendon insufficiency and muscle and skin contractions at flexor and thenar regions. In congenital clasped thumb success of treatment depends on lesion type. Although successful results have been obtained with splinting and conservative treatment, several reconstruction methods are used due to secondarily developed contractures in neglected cases. Tendon transfers are useful in hypermobile thumb cases who have both extensor and opponents tendon deficiency.

Official Title
-----------------
Different Modalities in Management of Congenial Clasped Thumb

Conditions
-----------------
Orthopedic Disorder

Intervention / Treatment
-----------------
* Procedure: widening of first web space


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Congenital clasped thumb Cerebral palsy Arthrogryposis Under age of eight years old. Exclusion Criteria: 1- Congenital trigger thumb. 2- Neglected adducted thumb. 3- Post traumatic extensor tendon injury. 4- Neglected congenital clasped thumb.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| widening<br>widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon | Procedure: widening of first web space<br>* widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improved hand grip degree | Measure the degree of thumb motion and improve function of the thumb to restore function of the hand abduction of the thumb more than 40 degree | 3 months |